Immunocore Holdings plc (IMCR): EBITDA
-$42.25M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$42.25M | n/m | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | -$66.26M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$55.55M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$46.41M | n/m | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | -$166.99M | n/a | 2024-02-28, From 2021-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$42.25M | n/m |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$111.41M | n/m |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $199.54M | +35.7% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$41.12M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $22.59M | +125.4% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$367.42M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $26.65M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $133.91M | +287.5% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $342.38M | n/m |
Compare IMCR, TWST, ADMA, ADPT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗